+

WO2006013014A3 - Diagnostics and therapeutics for diseases associated with prostate-specific membrane antigen-like protein (psmal) - Google Patents

Diagnostics and therapeutics for diseases associated with prostate-specific membrane antigen-like protein (psmal) Download PDF

Info

Publication number
WO2006013014A3
WO2006013014A3 PCT/EP2005/007953 EP2005007953W WO2006013014A3 WO 2006013014 A3 WO2006013014 A3 WO 2006013014A3 EP 2005007953 W EP2005007953 W EP 2005007953W WO 2006013014 A3 WO2006013014 A3 WO 2006013014A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
psmal
therapeutics
diagnostics
prostate
Prior art date
Application number
PCT/EP2005/007953
Other languages
French (fr)
Other versions
WO2006013014A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts filed Critical Bayer Healthcare Ag
Publication of WO2006013014A2 publication Critical patent/WO2006013014A2/en
Publication of WO2006013014A3 publication Critical patent/WO2006013014A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides a human PSMAL which is associated with the cardiovascular diseases, cancer, endocrinological diseases, metabolic diseases, gastroenterological diseases, inflammation, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases, urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, cancer, endocrinological diseases, metabolic diseases, gastroenterological diseases, inflammation, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases, urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of PSMAL as well as pharmaceutical compositions comprising such compounds.
PCT/EP2005/007953 2004-08-04 2005-07-21 Diagnostics and therapeutics for diseases associated with prostate-specific membrane antigen-like protein (psmal) WO2006013014A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04018441.8 2004-08-04
EP04018441 2004-08-04

Publications (2)

Publication Number Publication Date
WO2006013014A2 WO2006013014A2 (en) 2006-02-09
WO2006013014A3 true WO2006013014A3 (en) 2006-03-30

Family

ID=35344658

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/007953 WO2006013014A2 (en) 2004-08-04 2005-07-21 Diagnostics and therapeutics for diseases associated with prostate-specific membrane antigen-like protein (psmal)

Country Status (1)

Country Link
WO (1) WO2006013014A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1448588A4 (en) 2001-10-23 2006-10-25 Psma Dev Company L L C Psma antibodies and protein multimers
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061605A1 (en) * 1999-04-09 2000-10-19 Sloan-Kettering Institute For Cancer Research Dna encoding the prostate-specific membrane antigen-like gene and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061605A1 (en) * 1999-04-09 2000-10-19 Sloan-Kettering Institute For Cancer Research Dna encoding the prostate-specific membrane antigen-like gene and uses thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BZDEGA TOMASZ ET AL: "The cloning and characterization of a second brain enzyme with NAAG peptidase activity", JOURNAL OF NEUROCHEMISTRY, vol. 89, no. 3, May 2004 (2004-05-01), pages 627 - 635, XP002355349, ISSN: 0022-3042 *
O'KEEFE D S ET AL: "CLONING AND CHARACTERIZATION OF THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN-LIKE GENE", PROCEEDINGS OF THE 91ST ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. SAN FRANCISCO, CA, APRIL 1 - 5, 2000, PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, PHILADELPHIA, PA : AACR, US, vol. VOL. 41, March 2000 (2000-03-01), pages 39, XP001147719 *
O'KEEFE D S ET AL: "COMPARATIVE ANALYSIS OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) VERSUS A PROSTATE-SPECIFIC MEMBRANE ANTIGEN-LIKE GENE", PROSTATE, WILEY-LISS, NEW YORK, NY, US, vol. 58, no. 2, 1 February 2004 (2004-02-01), pages 200 - 210, XP009056468, ISSN: 0270-4137 *
O'KEEFE D S ET AL: "COMPARATIVE ANALYSIS OF THE PSMA AND PSMA-LIKE GENES YIELDS SOME SURPRISING INSIGHTS", PROCEEDINGS OF THE 91ST ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. SAN FRANCISCO, CA, APRIL 1 - 5, 2000, PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, PHILADELPHIA, PA : AACR, US, vol. VOL. 41, March 2000 (2000-03-01), pages 393, XP001147721 *
SMITH M W ET AL: "Identification of novel tumor markers in hepatitis C virus-associated hepatocellular carcinoma", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 63, 15 February 2003 (2003-02-15), pages 859 - 864, XP002978060, ISSN: 0008-5472 *
TSAI S J: "Strategies to increase central N-acetyl aspartylglutamate: A potential treatment for schizophrenia and bipolar disorders", SCHIZOPHRENIA RESEARCH, ELSEVIER, vol. 76, no. 2-3, 15 July 2005 (2005-07-15), pages 359 - 360, XP004931653, ISSN: 0920-9964 *

Also Published As

Publication number Publication date
WO2006013014A2 (en) 2006-02-09

Similar Documents

Publication Publication Date Title
WO2006027147A3 (en) Diagnostics and therapeutics for diseases associated with adrenomedullin receptor (amdr)
WO2005093092A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 44 (gpr44)
WO2005106012A3 (en) Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1)
WO2006010517A3 (en) Diagnostics and therapeutics for diseases associated with fibroblast activation protein (fap)
WO2005114207A3 (en) Diagnostics and therapeutics for diseases associated with aminopeptidase n (anpep)
WO2005103684A3 (en) Diagnostics and therapeutics for diseases associated with cx3c chemokine receptor 1 (cx3cr1)
WO2006013014A3 (en) Diagnostics and therapeutics for diseases associated with prostate-specific membrane antigen-like protein (psmal)
WO2006021343A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine receptor 3a (5-ht3a)
WO2005076007A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y12 (p2y12)
WO2005075675A3 (en) Diagnostics and therapeutics for diseases associated with putative cysteine protease 1 (prs1)
WO2005113786A3 (en) Diagnostics and therapeutics for diseases associated with chymase (cma1)
WO2006010514A3 (en) Diagnostics and therapeutics for diseases associated with dual specificity mitogen-activated protein kinase kinase 5 (map2k5)
WO2005090994A3 (en) Diagnostics and therapeutics for diseases associated with protein kinase, cgmp-dependent, type i (prkg1)
WO2006013013A3 (en) Diagnostics and therapeutics for diseases associated with protective protein for beta-galactosidase (ppgb)
WO2005106486A3 (en) Diagnostic and therapeutics for diseases associated with dipeptidyl-peptidase 3(dpp3)
WO2005101011A3 (en) Diagnostics and therapeutics for diseases associated with lxr-alpha (lxra)
WO2005026719A3 (en) Diagnostics and therapeutics for diseases associated with transporter slc22a3 (slc22a3)
WO2005073729A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y11 (p2y11)
WO2006040047A3 (en) Diagnostics and therapeutics for diseases associated with rho/rac-interacting citron kinase (cit)
WO2006008007A3 (en) Diagnostics and therapeutics for diseases associated with retinoid-inducible serine carboxypeptidase (risc)
WO2006013015A3 (en) Diagnostics and therapeutics for diseases associated with marapsin (mpn)
WO2005040791A3 (en) Diagnostics and therapeutics for diseases associated with somatostatin- and angiogenin-like peptide receptor (salpr)
WO2005119263A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 92 (gpr92)
WO2005085469A3 (en) Diagnostics and therapeutics for diseases associated with rho-associated protein kinase 1 (rock1)
WO2006010497A3 (en) Diagnostics and therapeutics for diseases associated with choline kinase (chk)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载